Condition: Cancer Gi · Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
The goal of this randomized controlled trial is to investigate the effectiveness and safety of Prophylactic EUS-gastroenterostomy (ProEUS-GE) as a preventative approach for malignant gastric outlet obstruction (MGOO) in men and women aged 18 years or older diagnosed with periampullary cancer. The main question this study aims to answer is can ProEUS-GE effectively prevent the occurrence of MGOO in patients with periampullary cancer? Patients will be randomly assigned to one of two groups: Group 1 (ERCP alone) or Group 2 (ERCP + ProEUS-GE). The study will compare the outcomes between these groups to determine the effectiveness of ProEUS-GE in preventing MGOO. Researchers will compare Group 1 (ERCP alone) with Group 2 (ERCP + ProEUS-GE) to see if the addition of ProEUS-GE leads to a reduced occurrence of MGOO in patients with periampullary cancer. The primary endpoint is the rate of malignant gastric outlet obstruction.
This description comes directly from the study's public registry record.
Yen-I Chen, MD · (514) 934-1934 · yen-i.chen@mgcill.com
Myriam Martel, MSc · myriam.martel@muhc.mcgill.ca
Always discuss trial participation with your own doctor first.
| Jewish General Hospital | Montreal, Canada | Not Yet Recruiting |
| McGill University Health Center | Montreal, Canada | Recruiting |
| St-Michael's Hospital (SMH) | Toronto, Canada | Not Yet Recruiting |
| Hôpital Privé des Peupliers | Paris, France | Not Yet Recruiting |
| Asian Institute of Gastroenterology | Hyderabad, India | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05994521